Sasha Jovanovic
3 min read
Haemonetics (HAE) just posted second quarter results that topped expectations, raised its full year revenue growth outlook, and pointed to a deeper CSL partnership that could support recurring plasma related sales.
Haemonetics has ridden a clear upswing, with the share price logging a 36.5% return over 90 days and 49.9% year to date. The 75.4% total shareholder return over the past 12 months points to momentum building as investors reassess both growth prospects and risk.
Scan for other healthcare stocks showing similar momentum and recurring revenue potential by reviewing our hand picked 35 healthcare AI stocks alongside Haemonetics.
Bulls see Haemonetics as a rerated compounder built on recurring plasma and hospital tech revenue. Bears see a hot stock that ran too far, too fast. Which story does the current valuation lean toward?
Most Popular Narrative: 4% Undervalued
Haemonetics closed at $119.93 against a widely followed fair value estimate of $124.50, which points to a modest valuation gap that hinges on recurring plasma and hospital earnings actually flowing through to cash.
The current numbers and this narrative’s view that Haemonetics is fairly valued imply that the share price already reflects meaningful recurring cash generation, margin expansion into the mid 20s, and continued execution on plasma and MedSurg growth without requiring a step change in performance.
See why 9 investors see Haemonetics as 4% undervalued.
Result: Fair Value of $124.50 (UNDERVALUED)
Still, the Haemonetics story can change quickly if CSL conversions slip behind plan or if tariff and self insured medical costs squeeze the margin narrative.
Find out about the key risks to this Haemonetics narrative.
Another View: Haemonetics Looks Expensive On Earnings
Haemonetics screens as undervalued on future cash flows, yet the P/E ratio tells a very different story. The stock trades at 52.5x earnings compared with 25.3x for the US Medical Equipment industry, peers at 38x, and a fair ratio of 31.7x based on Simply Wall St regression work. That gap points to real valuation risk if sentiment cools or execution stumbles. Which signal do you weigh more heavily?
To pressure test that earnings based view against the broader numbers, take a closer look at how current pricing stacks up against the fair ratio and peers with See what the numbers say about this price — find out in our valuation breakdown.
Next Steps
Sentiment on Haemonetics is clearly split. Move fast, grab the key numbers, and stress test them against your own expectations using the 2 key rewards and 3 important warning signs.
